RxLedger

Amneal Pharmace — Medicare Part D spending

Rank #21 by attributed Part D spend · 67 tracked drugs · CMS data year 2023

About $2,591,591,867 of Medicare Part D spending in 2023 is attributed to Amneal Pharmace across the 67 of its drugs tracked here, ranking it #21 among manufacturers on this site. Its biggest Part D drug is Levothyroxine Sodium* at $653,594,902. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Amneal Pharmace drugs in Medicare Part D (2023)

BrandGenericTotal spendPer dosage unitBeneficiariesSpend rank
<a href="/drug/levothyroxine-sodium-levothyroxine-sodium/">Levothyroxine Sodium*</a>Levothyroxine Sodium$653,594,902$0.258,687,969#81
<a href="/drug/ezetimibe-ezetimibe/">Ezetimibe</a>Ezetimibe$290,177,168$0.571,921,217#166
<a href="/drug/rytary-carbidopa-levodopa/">Rytary</a>Carbidopa/Levodopa$266,869,488$4.4932,157#182
<a href="/drug/sucralfate-sucralfate/">Sucralfate</a>Sucralfate$160,271,432$0.32800,942#280
<a href="/drug/divalproex-sodium-er-divalproex-sodium/">Divalproex Sodium ER</a>Divalproex Sodium$120,375,972$0.93232,066#342
<a href="/drug/buprenorphine-buprenorphine/">Buprenorphine</a>Buprenorphine$119,900,450$80.0774,893#343
SpironolactoneSpironolactone$101,773,696$0.192,081,937#387
Bumetanide*Bumetanide$98,372,371$0.58522,275#398
UrsodiolUrsodiol$97,745,976$1.67102,032#401
Tramadol HClTramadol HCl$91,679,129$0.113,884,717#423
Propranolol HCl*Propranolol HCl$73,121,335$0.23671,925#491
Fluphenazine HCl*Fluphenazine HCl$49,822,433$3.8925,724#617
Colestipol HClColestipol HCl$46,835,796$0.83141,803#638
PrimidonePrimidone$40,620,887$0.23279,909#675
Budesonide ECBudesonide$37,307,677$3.0446,342#708
YuvafemEstradiol$29,090,930$8.1860,394#805
Oxymorphone HCl EROxymorphone HCl$27,458,812$12.143,885#829
EtravirineEtravirine$26,610,172$17.022,742#844
Pyridostigmine BromidePyridostigmine Bromide$25,515,944$0.6056,300#862
NitrofurantoinNitrofurantoin Macrocrystal$24,626,891$1.11313,690#882
DifluprednateDifluprednate$21,536,113$26.7969,636#932
Hydroxyzine PamoateHydroxyzine Pamoate$20,653,891$0.18419,149#944
Niacin ERNiacin$18,332,378$1.2142,698#993
Fludrocortisone AcetateFludrocortisone Acetate$13,046,506$0.45110,294#1131
Alosetron HClAlosetron HCl$12,657,281$17.812,223#1145
Bethanechol ChlorideBethanechol Chloride$11,983,605$0.5744,613#1162
FelbamateFelbamate$11,253,934$2.382,759#1183
DottiEstradiol$9,911,458$7.8524,304#1229
ItraconazoleItraconazole$9,500,824$2.6413,522#1258
Atropine Sulfate*Atropine Sulfate$9,184,134$9.07109,532#1266
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol$7,273,801$2.1511,137#1362
Oxycodone HCl EROxycodone HCl$6,461,702$7.805,310#1405
Acebutolol HClAcebutolol HCl$5,641,077$0.6618,164#1458
MetyrosineMetyrosine$5,520,238$328.8220#1462
EmvermMebendazole$5,029,155$643.031,226#1493
Guanfacine HClGuanfacine HCl$4,656,029$0.6522,464#1523
Tramadol HCl-AcetaminophenTramadol HCl/Acetaminophen$4,474,513$0.25120,732#1540
Dantrolene SodiumDantrolene Sodium$4,034,773$0.876,406#1574
Cyclobenzaprine HCl ERCyclobenzaprine HCl$3,316,183$16.631,385#1655
Frovatriptan SuccinateFrovatriptan Succinate$3,312,684$28.961,913#1656

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Frequently asked questions

How much Medicare Part D spending does Amneal Pharmace get?

In 2023, about $2,591,591,867 of Medicare Part D spending is attributed to Amneal Pharmace across the 67 of its drugs tracked here. Its biggest is Levothyroxine Sodium* at $653,594,902. This is gross program spending, not what patients pay. Source: CMS, data year 2023.

What is Amneal Pharmace's top Medicare Part D drug?

Among the drugs tracked here, Amneal Pharmace's highest Part D spending in 2023 is Levothyroxine Sodium* at $653,594,902 (national rank #81 by total spend).

Is manufacturer attribution exact?

No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.

Keep exploring

Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-21